Medexus Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MEDEXUS
MEDEXUS has two approved drugs.
There are two US patents protecting MEDEXUS drugs.
There are fifty-one patent family members on MEDEXUS drugs in twenty-six countries and six supplementary protection certificates in six countries.
Summary for Medexus
| International Patents: | 51 |
| US Patents: | 2 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Medexus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medexus | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-010 | Jul 10, 2014 | RX | Yes | Yes | 8,664,231 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Medexus | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-009 | Jul 10, 2014 | DISCN | Yes | No | 8,664,231 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Medexus | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-001 | Jul 10, 2014 | RX | Yes | Yes | 8,664,231 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Medexus | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-008 | Jul 10, 2014 | RX | Yes | Yes | 8,664,231 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Medexus | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-006 | Jul 10, 2014 | RX | Yes | Yes | 8,664,231 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Medexus | GRAFAPEX | treosulfan | POWDER;INTRAVENOUS | 214759-001 | Jan 21, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Medexus | GRAFAPEX | treosulfan | POWDER;INTRAVENOUS | 214759-001 | Jan 21, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Medexus Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Austria | 14872 | ⤷ Start Trial |
| Poland | 212132 | ⤷ Start Trial |
| South Korea | 20090079876 | ⤷ Start Trial |
| Norway | 20022109 | ⤷ Start Trial |
| Hungary | P0203277 | ⤷ Start Trial |
| Hungary | 227332 | ⤷ Start Trial |
| Japan | 5683810 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Medexus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1227808 | 122019000073 | Germany | ⤷ Start Trial | PRODUCT NAME: TREOSULFAN; REGISTRATION NO/DATE: EU/1/18/1351 20190620 |
| 1227808 | 1990039-8 | Sweden | ⤷ Start Trial | PRODUCT NAME: TREOSULFAN; REG. NO/DATE: EU/1/18/1351 20190624 |
| 1227808 | SPC/GB19/052 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: TREOSULFAN; REGISTERED: UK EU/1/18/1351 20190624 |
| 1227808 | C201930050 | Spain | ⤷ Start Trial | PRODUCT NAME: TREOSULFANO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1351; DATE OF AUTHORISATION: 20190620; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1351; DATE OF FIRST AUTHORISATION IN EEA: 20190620 |
| 1227808 | 132019000000108 | Italy | ⤷ Start Trial | PRODUCT NAME: TREOSULFAN(TRECONDI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1351, 20190624 |
| 1227808 | 301002 | Netherlands | ⤷ Start Trial | PRODUCT NAME: TREOSULFAN; REGISTRATION NO/DATE: EU/1/18/1351 20190620 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
